Peng Men
Overview
Explore the profile of Peng Men including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
155
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wang C, Dong Y, Men P, Zhang R, Xiao Y, Bu Y, et al.
Front Pharmacol
. 2025 Jan;
15():1426772.
PMID: 39830356
Background: Obinutuzumab was approved in China in June 2021 used in combination with chemotherapy (followed by obinutuzumab maintenance) for the treatment of adult patients with previously untreated stage II bulky,...
2.
Zeng L, Yi Q, Huang L, Chen W, Men P, Zhang J, et al.
J Evid Based Med
. 2022 Sep;
15(3):272-283.
PMID: 36178674
Aim: The guideline is meant to standardize the principles, procedures, and methods for developing therapeutic drug monitoring (TDM) guidelines and promoting open, transparent, scientific, and credible TDM guidelines. Methods: Division...
3.
Li X, Ma Q, Yin J, Zheng Y, Chen R, Chen Y, et al.
Front Pharmacol
. 2022 Apr;
13:845689.
PMID: 35418863
For anaphylaxis, a life-threatening allergic reaction, the incidence rate was presented to have increased from the beginning of the 21st century. Underdiagnosis and undertreatment of anaphylaxis are public health concerns....
4.
Zhou P, Zheng S, Wang E, Men P, Zhai S
Front Pharmacol
. 2021 Oct;
12:696201.
PMID: 34712132
Conbercept is a new anti-vascular endothelial growth factor (VEGF) drug. Here, we systematically conducted the efficacy, safety, compliance, and pharmacoeconomic evaluation of intravitreal conbercept (IVC) compared with other treatments in...
5.
Qiu T, Men P, Sun T, Zhai S
Front Public Health
. 2021 Sep;
9:660514.
PMID: 34513778
The aim of this systematic review is to assess the published cost-effectiveness analyses of aprepitant for patients with chemotherapy-induced nausea and vomiting (CINV). A systematic literature search was performed on...
6.
Dong S, Qi H, Li Y, Men P, Alifu M, Zhang Y, et al.
Hepatol Int
. 2021 Sep;
15(6):1356-1375.
PMID: 34487316
Purpose: To date, the optimal treatment for portal vein thrombosis (PVT) in cirrhotic patients has not been established in guidelines or consensus. We conducted a systematic review and meta-analysis to...
7.
Ramos M, Men P, Wang X, Ustyugova A, Lamotte M
Cost Eff Resour Alloc
. 2021 Aug;
19(1):46.
PMID: 34348729
Background: In several cardiovascular outcome trials (CVOTs), empagliflozin (SGLT-2 inhibitor), sitagliptin (DPP-4 inhibitor) and liraglutide (GLP-1 receptor agonist) + standard of care (SoC) were compared to SoC in patients with...
8.
Salem A, Men P, Ramos M, Zhang Y, Ustyugova A, Lamotte M
J Comp Eff Res
. 2021 Feb;
10(6):469-480.
PMID: 33576249
The study assesses the cost-effectiveness of empagliflozin versus glimepiride in patients with Type 2 diabetes and uncontrolled by metformin alone in China, based on the EMPA-REG H2H-SU trial. A calibrated...
9.
Qiu T, Men P, Xu X, Zhai S, Cui X
Medicine (Baltimore)
. 2020 Sep;
99(33):e21559.
PMID: 32872006
Objective: To systematically evaluate the efficacy and safety of antiemetic regimen with aprepitant in the prevention of chemotherapy-induced nausea and vomiting (CINV) and provide updated information for clinical practice. Methods:...
10.
Men P, Liu T, Zhai S
Diabetes Metab Syndr Obes
. 2020 Aug;
13:2823-2831.
PMID: 32848438
Purpose: To evaluate the cost-utility of empagliflozin, in addition to best available standard care (BASC), for the treatment of adult patients with T2DM at high cardiovascular risk from the Chinese...